Company intelligence / Profile preview

Wanbang Biopharmaceuticals

Xuzhou, Jiangsu, Chinachinawanbang.com ↗

Ownership: Private
Employees: ~5000
Development stage: Commercial

Overview

The company has a strong commercial portfolio with leading positions in diabetes care and related chronic diseases. It has several approved recombinant insulins and analogues, EPO products, heparin sodium, febuxostat tablets for hyperuricemia/gout, glimepiride tablets for diabetes, calcium dobesilate capsules for vascular complications. Some innovative programs are in late-stage clinical trials or registration phases.

Therapeutic areas: Metabolic DisordersOncologyEndocrinologyRheumatologyCardiovascularNephrology
Modalities: Small moleculeRecombinant proteinBiosimilarHormoneHerbal medicineBiologic
Industry: Biotech

Drug pipeline

4 assets

VT-101

Unknown

3 more assets in the full pipeline.

Request access →

Partnerships

D-Pharm Israel

Beyond the preview

Go deeper on Wanbang Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wanbang Biopharmaceuticals.

Explore the full profile